Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, emphasizes the influence of comorbidities on therapeutic decisions in patients with chronic lymphocytic leukemia (CLL), including bulky disease, risk of tumor lysis syndrome, poor renal function, and impaired cardiac function. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.